文献速递慢性肾脏病急性肾损伤

GLP-1受体激动剂在CKD合并2型糖尿病中的脓毒症与感染结局

Sepsis and Infectious Outcomes for GLP-r Agonists in CKD plus Type 2 Diabetes.
PubMed 文献 · Nephrol Dial Transplant · 2026-08-07

GLP-1RA组脓毒症风险低于DPP-4i组(HR=0.72;95%CI 0.66-0.78),全因死亡、肺炎、尿路感染和COVID-19风险亦较低,感染性休克风险两组相似。

要点

  • CKD合并2型糖尿病患者使用GLP-1RA较DPP-4i脓毒症风险更低(HR=0.72)。
  • GLP-1RA组全因死亡、肺炎、尿路感染和COVID-19风险均显著低于DPP-4i组。
  • 感染性休克风险数值上较低但未达Bonferroni校正显著性,组间相似。

核心结论

  • 在CKD合并2型糖尿病患者中,GLP-1RA使用与脓毒症、全因死亡、肺炎、尿路感染和COVID-19风险降低相关,感染性休克风险两组相似。

研究设计与样本

  • 利用TriNetX数据库开展回顾性队列研究,纳入2020年1月至2026年5月起始GLP-1RA或DPP-4i的CKD合并2型糖尿病成人患者。

主要发现

  • GLP-1RA组脓毒症风险低于DPP-4i组(HR=0.72;95%CI 0.66-0.78)。
  • GLP-1RA组全因死亡风险低于DPP-4i组(HR=0.65;95%CI 0.61-0.70)。
  • GLP-1RA组肺炎风险低于DPP-4i组(HR=0.81;95%CI 0.75-0.87)。
  • GLP-1RA组尿路感染风险低于DPP-4i组(HR=0.83;95%CI 0.79-0.88)。
  • GLP-1RA组COVID-19风险低于DPP-4i组(HR=0.84;95%CI 0.77-0.90);感染性休克风险数值上较低但未达Bonferroni校正显著性(HR=0.84;95%CI 0.73-0.96;P=0.014)。

临床怎么用

  • 对于CKD合并2型糖尿病患者,选择GLP-1RA而非DPP-4i可能有助于降低脓毒症及部分感染风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chronic kidney disease (CKD) is associated with a higher risk of sepsis and poorer clinical outcomes compared to the general population. While GLP-1 receptor agonists (GLP-1RA) may confer protective effects against sepsis beyond their metabolic benefits in patients with diabetes, their effect in CKD patients remains unclear. This study aims to evaluate the association between GLP-1RA therapy and infectious outcomes in patients with CKD. METHODS: Using the TriNetX database, we conducted a retrospective cohort study of adults with CKD and type 2 diabetes mellitus initiating GLP-1RAs or dipeptidyl peptidase-4 inhibitors (DPP-4i) between January 2020 and May 2026. The primary outcome was sepsis. Secondary outcomes included all-cause mortality, septic shock, pneumonia, urinary tract infection, and COVID-19. RESULTS: After propensity score matching, 21 035 patients were included in each treatment group. Use of GLP-1RA was associated with a lower risk of sepsis compared with DPP-4i (HR = 0.72; 95% CI, 0.66-0.78). GLP-1RA use was also associated with lower risks of all-cause mortality (HR = 0.65; 95% CI, 0.61-0.70), pneumonia (HR = 0.81; 95% CI, 0.75-0.87), urinary tract infection (HR = 0.83; 95% CI, 0.79-0.88), and COVID-19 (HR = 0.84; 95% CI, 0.77-0.90). The risk of septic shock did not reach Bonferroni-corrected significance level despite being numerically lower (HR = 0.84; 95% CI, 0.73-0.96; P = 0.014). CONCLUSIONS: In patients with CKD and type 2 diabetes mellitus, use of GLP-1RA is associated with lower risks of sepsis, all-cause mortality, pneumonia, urinary tract infection, and COVID-19 compared with DPP-4i, while the risk of septic shock was similar between groups.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Tseng YY, Wang HY, Chen JY, et al. Sepsis and Infectious Outcomes for GLP-r Agonists in CKD plus Type 2 Diabetes. Nephrol Dial Transplant. 2026. PMID: 42566276. doi:10.1093/ndt/gfag175

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。